“The role of genomic testing in bladder is expanding almost every year,” says Faltas.
Bishoy M. Faltas, MD, assistant professor of Medicine at Weill Cornell Medicine, explains the growing role of genomic testing in bladder cancer, including the emerging understanding of the role of germline alterations.
Vobramitamab duocarmazine continues to show promise in mCRPC
May 10th 2024Updated data from the phase 2 TAMARCK study continued to show safety and preliminary efficacy with the B7-H3–targeting antibody-drug conjugate vobramitamab duocarmazine in patients with metastatic castration-resistant prostate cancer.